Market revenue in 2022 | USD 672.1 million |
Market revenue in 2030 | USD 1,198.4 million |
Growth rate | 7.5% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.95% in 2022. Horizon Databook has segmented the Spain hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Spain is a lucrative market for hormone replacement therapy owing to the growing prevalence of target disorders, good access to healthcare, improving diagnosis facilities, growing healthcare expenditure as a share of GDP, technological advancements, and rising adoption of novel therapeutic options for their treatment.
Nearly all the residents are covered under public health insurance. However, the government only funds 71% of the health spending, whereas the rest of the health spending is out-of-pocket (which also includes medication). Turner syndrome affects 25 to 50 per 100.000 females at birth in Spain. Several organizations in the country are raising awareness and guiding patients toward appropriate treatments.
Turner Syndrome Foundation is a prominent local organization generating awareness about the disease and raising funds for the same. In addition, it maintains a registry and provides information & guidance to caregivers at no cost. Increase in awareness about GHD and related disorders in Spain is expected to propel market growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Spain hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account